Literature DB >> 32125282

DNA hypermethylation during tuberculosis dampens host immune responsiveness.

Andrew R DiNardo1, Kimal Rajapakshe2, Tomoki Nishiguchi1, Sandra L Grimm2, Godwin Mtetwa3, Qiniso Dlamini3, Jaqueline Kahari3, Sanjana Mahapatra1, Alexander Kay3, Gugu Maphalala4, Emily M Mace5, George Makedonas6, Jeffrey D Cirillo7, Mihai G Netea8, Reinout van Crevel8, Cristian Coarfa2, Anna M Mandalakas1.   

Abstract

Mycobacterium tuberculosis (M. tuberculosis) has coevolved with humans for millennia and developed multiple mechanisms to evade host immunity. Restoring host immunity in order to improve outcomes and potentially shorten existing therapy will require identification of the full complement by which host immunity is inhibited. Perturbation of host DNA methylation is a mechanism induced by chronic infections such as HIV, HPV, lymphocytic choriomeningitis virus (LCMV), and schistosomiasis to evade host immunity. Here, we evaluated the DNA methylation status of patients with tuberculosis (TB) and their asymptomatic household contacts and found that the patients with TB have DNA hypermethylation of the IL-2/STAT5, TNF/NF-κB, and IFN-γ signaling pathways. We performed methylation-sensitive restriction enzyme-quantitative PCR (MSRE-qPCR) and observed that multiple genes of the IL-12/IFN-γ signaling pathway (IL12B, IL12RB2, TYK2, IFNGR1, JAK1, and JAK2) were hypermethylated in patients with TB. The DNA hypermethylation of these pathways was associated with decreased immune responsiveness with decreased mitogen-induced upregulation of IFN-γ, TNF, IL-6, CXCL9, CXCL10, and IL-1β production. The DNA hypermethylation of the IL-12/IFN-γ pathway was associated with decreased IFN-γ-induced gene expression and decreased IL-12-inducible upregulation of IFN-γ. This study demonstrates that immune cells from patients with TB are characterized by DNA hypermethylation of genes critical to mycobacterial immunity resulting in decreased mycobacteria-specific and nonspecific immune responsiveness.

Entities:  

Keywords:  Cytokines; Epigenetics; Immunology; Infectious disease; Tuberculosis

Mesh:

Year:  2020        PMID: 32125282      PMCID: PMC7260034          DOI: 10.1172/JCI134622

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Gene-specific control of inflammation by TLR-induced chromatin modifications.

Authors:  Simmie L Foster; Diana C Hargreaves; Ruslan Medzhitov
Journal:  Nature       Date:  2007-05-30       Impact factor: 49.962

2.  Automated identification of stratifying signatures in cellular subpopulations.

Authors:  Robert V Bruggner; Bernd Bodenmiller; David L Dill; Robert J Tibshirani; Garry P Nolan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

Review 3.  T cell exhaustion during persistent viral infections.

Authors:  Shannon M Kahan; E John Wherry; Allan J Zajac
Journal:  Virology       Date:  2015-01-22       Impact factor: 3.616

4.  The transcription factor NFAT promotes exhaustion of activated CD8⁺ T cells.

Authors:  Gustavo J Martinez; Renata M Pereira; Tarmo Äijö; Edward Y Kim; Francesco Marangoni; Matthew E Pipkin; Susan Togher; Vigo Heissmeyer; Yi Chen Zhang; Shane Crotty; Edward D Lamperti; K Mark Ansel; Thorsten R Mempel; Harri Lähdesmäki; Patrick G Hogan; Anjana Rao
Journal:  Immunity       Date:  2015-02-10       Impact factor: 31.745

5.  Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment.

Authors:  Edhyana Sahiratmadja; Bachti Alisjahbana; Tjitske de Boer; Iskandar Adnan; Anugrah Maya; Halim Danusantoso; Ronald H H Nelwan; Sangkot Marzuki; Jos W M van der Meer; Reinout van Crevel; Esther van de Vosse; Tom H M Ottenhoff
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

6.  Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values.

Authors:  Frank G Cobelens; Saidi M Egwaga; Tessa van Ginkel; Hemed Muwinge; Mecky I Matee; Martien W Borgdorff
Journal:  Clin Infect Dis       Date:  2006-07-12       Impact factor: 9.079

7.  Well-quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection.

Authors:  A M Mandalakas; H L Kirchner; C Lombard; G Walzl; H M S Grewal; R P Gie; A C Hesseling
Journal:  Int J Tuberc Lung Dis       Date:  2012-06-11       Impact factor: 2.373

8.  The Molecular Signatures Database (MSigDB) hallmark gene set collection.

Authors:  Arthur Liberzon; Chet Birger; Helga Thorvaldsdóttir; Mahmoud Ghandi; Jill P Mesirov; Pablo Tamayo
Journal:  Cell Syst       Date:  2015-12-23       Impact factor: 10.304

9.  Anergy in active pulmonary tuberculosis. A comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses.

Authors:  D R Nash; J E Douglass
Journal:  Chest       Date:  1980-01       Impact factor: 9.410

10.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

Authors:  Stephen H Gillespie; Angela M Crook; Timothy D McHugh; Carl M Mendel; Sarah K Meredith; Stephen R Murray; Frances Pappas; Patrick P J Phillips; Andrew J Nunn
Journal:  N Engl J Med       Date:  2014-09-07       Impact factor: 91.245

View more
  17 in total

Review 1.  Postinfectious Epigenetic Immune Modifications - A Double-Edged Sword.

Authors:  Andrew R DiNardo; Mihai G Netea; Daniel M Musher
Journal:  N Engl J Med       Date:  2021-01-21       Impact factor: 91.245

2.  Tuberculosis endotypes to guide stratified host-directed therapy.

Authors:  Andrew R DiNardo; Tomoki Nishiguchi; Sandra L Grimm; Larry S Schlesinger; Edward A Graviss; Jeffrey D Cirillo; Cristian Coarfa; Anna M Mandalakas; Jan Heyckendorf; Stefan H E Kaufmann; Christoph Lange; Mihai G Netea; Reinout Van Crevel
Journal:  Med (N Y)       Date:  2021-01-16

Review 3.  The Role of Host Cell DNA Methylation in the Immune Response to Bacterial Infection.

Authors:  Wanhai Qin; Brendon P Scicluna; Tom van der Poll
Journal:  Front Immunol       Date:  2021-07-29       Impact factor: 7.561

Review 4.  New insights into the evasion of host innate immunity by Mycobacterium tuberculosis.

Authors:  Qiyao Chai; Lin Wang; Cui Hua Liu; Baoxue Ge
Journal:  Cell Mol Immunol       Date:  2020-07-29       Impact factor: 11.530

5.  Advances in Nutritional Epigenetics-A Fresh Perspective for an Old Idea. Lessons Learned, Limitations, and Future Directions.

Authors:  Lynda Sedley
Journal:  Epigenet Insights       Date:  2020-12-18

Review 6.  The definition of tuberculosis infection based on the spectrum of tuberculosis disease.

Authors:  Giovanni Battista Migliori; Catherine W M Ong; Linda Petrone; Lia D'Ambrosio; Rosella Centis; Delia Goletti
Journal:  Breathe (Sheff)       Date:  2021-09

7.  Deciphering a TB-related DNA methylation biomarker and constructing a TB diagnostic classifier.

Authors:  Mengyuan Lyu; Jian Zhou; Lin Jiao; Yili Wang; Yanbing Zhou; Hongli Lai; Wei Xu; Binwu Ying
Journal:  Mol Ther Nucleic Acids       Date:  2021-11-19       Impact factor: 8.886

Review 8.  Understanding the tuberculosis granuloma: the matrix revolutions.

Authors:  Paul Elkington; Marta E Polak; Michaela T Reichmann; Alasdair Leslie
Journal:  Trends Mol Med       Date:  2021-12-15       Impact factor: 11.951

Review 9.  Reversing Post-Infectious Epigenetic-Mediated Immune Suppression.

Authors:  Carlos O Ontiveros; Rosa S Guerra-Resendez; Tomoki Nishiguchi; Malik Ladki; Isaac B Hilton; Larry S Schlesinger; Andrew R DiNardo
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 8.786

Review 10.  Perspective for Precision Medicine for Tuberculosis.

Authors:  Christoph Lange; Rob Aarnoutse; Dumitru Chesov; Reinout van Crevel; Stephen H Gillespie; Hans-Peter Grobbel; Barbara Kalsdorf; Irina Kontsevaya; Arjan van Laarhoven; Tomoki Nishiguchi; Anna Mandalakas; Matthias Merker; Stefan Niemann; Niklas Köhler; Jan Heyckendorf; Maja Reimann; Morten Ruhwald; Patricia Sanchez-Carballo; Dominik Schwudke; Franziska Waldow; Andrew R DiNardo
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.